Antiangiogenic agents: current limits in thoracic oncology

被引：0
|
作者：
Dansin, Eric [1 ]
Lauridant, Geraldine [1 ]
Chahine, Bachar [1 ]
机构：
[1] CLCC Oscar Lambret, Dept Cancerol Gen, F-59020 Lille, France
来源：
BULLETIN DU CANCER | 2012年 / 99卷 / 11期
关键词：
antiangiogenic agent; multi-targeted tyrosine kinase inhibitor; bevacizumab; lung cancer; thoracic oncology; CELL-LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED PHASE-II; ANGIOGENESIS INHIBITOR BEVACIZUMAB; ARTERIAL THROMBOEMBOLIC EVENTS; PACLITAXEL PLUS BEVACIZUMAB; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; COST-EFFECTIVENESS; 1ST-LINE BEVACIZUMAB;
D O I：
10.1684/bdc.2012.1655
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.
引用
收藏
页码：1083 / 1091
页数：9
相关论文
共 50 条
  • [1] Current antiangiogenic agents in oncology and ophthalmology
    Cernak, M.
    Nogova, L.
    NEOPLASMA, 2016, 63 (01) : 10 - 17
  • [2] Reflections on the limits of specific treatments in thoracic oncology
    Dansin, E.
    Lauridant, G.
    Reich, M.
    Villet, S.
    Fournel, P.
    REVUE DES MALADIES RESPIRATOIRES, 2015, 32 (02) : 166 - 172
  • [3] Antiangiogenic therapy in oncology: current status and future directions
    Jayson, Gordon C.
    Kerbel, Robert
    Ellis, Lee M.
    Harris, Adrian L.
    LANCET, 2016, 388 (10043): : 518 - 529
  • [4] Clinical characteristics associated with cardiovascular toxicity of antiangiogenic agents in oncology
    Rousseau, B.
    Boissier, E.
    Soria, J. C.
    Goldwasser, F.
    Tournigand, C.
    Spano, J. P.
    Macquin-Mavier, I.
    Mir, O.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 27 - 27
  • [5] Current and Evolving Surgical Strategies in Thoracic Oncology
    K. Harish
    Indian Journal of Surgical Oncology, 2013, 4 (2) : 94 - 95
  • [6] Current and Evolving Surgical Strategies in Thoracic Oncology
    Harish, K.
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2013, 4 (02) : 94 - 95
  • [7] Antiangiogenic Agents
    Di Donna, Anna
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (35) : 3862 - 3863
  • [8] Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents
    Lau, Brianna C.
    Wu, Yufan F.
    No, Hyunsoo J.
    Ko, Ryan B.
    Devine, Max D.
    Das, Millie S.
    Neal, Joel W.
    Wakelee, Heather A.
    Ramchandran, Kavitha
    Gensheimer, Michael F.
    Diehn, Maximilian
    Chin, Alexander L.
    Loo Jr, Billy W.
    Vitzthum, Lucas K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (07) : 922 - 930
  • [9] Antiangiogenic agents
    Klohs, WD
    Hamby, JM
    CURRENT OPINION IN BIOTECHNOLOGY, 1999, 10 (06) : 544 - 549
  • [10] Antiangiogenic agents
    Stani, SC
    Capaccetti, B
    Bonginelli, P
    Sarmiento, R
    De Sio, L
    Fanelli, M
    Gasparini, G
    TUMORI JOURNAL, 2002, : S39 - S43
12345